At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,057 enrolled
Drug / intervention
Ergoferon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Ergoferon as Non-specific COVID-19 Prevention During Vaccination Against SARS-CoV-2
In Brief
A Phase 3 clinical trial evaluating Ergoferon and Placebo for Immunization Against COVID-19. Completed, enrolled 1,057 participants across 33 sites.
Detailed Summary
The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Ergoferon as a non-specific preventive medicine for COVID-19 in individuals vaccinated against a new coronavirus infection (SARS-CoV-2)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunization Against COVID-19
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartOct 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedOct 6, 2021
Enrollment StartOct 6, 2021
Primary CompletionApr 14, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.7 years ago
Interventions
Ergoferondrug
Tablet for oral use.
Placebodrug
Tablet for oral use.